Pascal and Francis Bibliographic Databases

Help

Export

Selection :

Permanent link
http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23033272

Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK

Author
LOGMAN, J. F. S1 ; HEEG, B. M. S1 ; BOTTEMAN, M. F2 ; KAURA, S3 ; VAN HOUT, B. A1
[1] Pharmerit Europe, Rotterdam, Netherlands
[2] Pharmerit North Amenca LLC, Bethesda, MD, United States
[3] Department of Health Economics, Novartis Pharmaceuticals Corporation, Florham Park, NJ, United States
Source

Annals of oncology. 2010, Vol 21, Num 7, pp 1529-1536, 8 p ; ref : 42 ref

ISSN
0923-7534
Scientific domain
Medical oncology; Pharmacology drugs
Publisher
Oxford University Press, Oxford
Publication country
United Kingdom
Document type
Article
Language
English
Author keyword
AIBL aromatase inhibitor bone loss breast cancer cost-effectiveness zoledronic acid
Keyword (fr)
Acide zolédronique Adulte Analyse coût efficacité Anticancéreux Antirésorptif Cancer du sein Economie santé Femelle Femme Fracture Homme Inhibiteur de l'aromatase Ménopause Ostéoporose Ostéopénie Perte de substance osseuse Postménopause Prévention Santé publique Stade précoce Royaume-Uni Antiostéoporotique Bisphosphonates Cancer Dérivé de l'acide diphosphonique Pathologie de la glande mammaire Pathologie du sein Pathologie du système ostéoarticulaire Traumatisme Tumeur maligne Europe
Keyword (en)
Zoledronic acid Adult Cost efficiency analysis Antineoplastic agent Antiresorptive agent Breast cancer Health economy Female Woman Fracture Human Aromatase inhibitor Menopause Osteoporosis Osteopenia Bone defect Postmenopause Prevention Public health Early stage United Kingdom Antiosteoporotic Bisphosphonates Cancer Diphosphonic acid derivatives Mammary gland diseases Breast disease Diseases of the osteoarticular system Trauma Malignant tumor Europe
Keyword (es)
Acido zoledrónico Adulto Análisis costo eficacia Anticanceroso Antirresortivo Cáncer del pecho Economía salud Hembra Mujer Fractura Hombre Inhibidor aromatase Menopausia Osteoporosis Osteopenia Pérdida substancia hueso Postmenopausia Prevención Salud pública Estadio precoz Reino Unido Antiosteoporótico Bisfosfonatos Cáncer Difosfonico ácido derivado Glándula mamaria patología Seno patología Sistema osteoarticular patología Traumatismo Tumor maligno Europa
Classification
Pascal
002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents

Pascal
002 Biological and medical sciences / 002B Medical sciences / 002B15 Diseases of the osteoarticular system / 002B15A Osteoporosis. Osteomalacia. Paget disease

Pascal
002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20E Mammary gland diseases / 002B20E02 Tumors

Discipline
Gynecology. Andrology. Obstetrics Osteoarticular pathology Pharmacological treatments
Origin
Inist-CNRS
Database
PASCAL
INIST identifier
23033272

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS

Access to the document

Searching the Web